Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation.
about
Current limitations of SNP data from the public domain for studies of complex disorders: a test for ten candidate genes for obesity and osteoporosisProspective single-site experience with radiofrequency-targeted vertebral augmentation for osteoporotic vertebral compression fractureAnabolic steroids for rehabilitation after hip fracture in older peopleBisphosphonate therapy for children and adolescents with secondary osteoporosisStatins for osteoporosis in postmenopausal womenSurgery for hip fractures: Does surgical delay affect outcomes?Balloon kyphoplasty in the management of vertebral compression fractures: an updated systematic review and meta-analysisHistory of fractures as predictor of subsequent hip and nonhip fractures among older Mexican AmericansLinkage of osteoporosis to chromosome 20p12 and association to BMP2Management of osteoporosisDifferential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional studyAssociation between a variation in the phosphodiesterase 4D gene and bone mineral densityFracture risk associated with the use of morphine and opiatesN-phenacylthiazolium bromide reduces bone fragility induced by nonenzymatic glycationGenes influencing spinal bone mineral density in inbred F344, LEW, COP, and DA ratsPowerful bivariate genome-wide association analyses suggest the SOX6 gene influencing both obesity and osteoporosis phenotypes in malesA guide to organizing a multicenter clinical trial.Hierarchy of Bone Microdamage at Multiple Length Scales.Self-reported calcium intake and bone mineral content in children and adolescents.Using vital statistics to estimate the population-level impact of osteoporotic fractures on mortality based on death certificates, with an application to France (2000-2004).Recent progress in understanding the genetic susceptibility to osteoporosis.Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat.The assessment of fracture risk.Osteoporosis: gender differences and similarities.Osteoporosis: implications for risk reduction in the college setting.Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture.An observational study of musculoskeletal pain among patients receiving bisphosphonate therapyTen years of hip fractures in Italy: For the first time a decreasing trend in elderly women.Osteoporosis Knowledge among Future Healthcare Practitioners: Findings from a Malaysian Public University.Functional consequences of sarcopenia and dynapenia in the elderly.Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA.Gene-gene interaction between RBMS3 and ZNF516 influences bone mineral density.Osteoporosis and bone densitometry: does the emperor have clothes?A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo.Bone densitometry: does the emperor have clothes?Postmenopausal osteoporosis. Strategies for preventing bone loss, avoiding fracture.alpha(v)beta(3) Integrin antagonists as inhibitors of bone resorption.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisCalcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis.
P2860
Q21283795-31CB142A-0FE8-43A5-8560-10BC0629859FQ21284770-EB472167-F721-4076-9063-FB837BC4BA5DQ24236209-3E054E6F-0A9D-490A-863A-FA97B945A2D8Q24243298-1EB7FEF6-DADC-40C7-AFB0-ED546564F3DFQ24243698-F001493D-1F11-4E9E-854A-0E66D83A116FQ24627414-7F96B913-5D30-4C73-80C0-5CB7BCFE438EQ24650936-BCC315CF-D009-4C50-B346-E3278BF446BBQ24651058-1D0D661B-9022-48F2-8250-D1AAD891AF6FQ24792039-AFA2C581-862C-4016-ABA8-2A1ED2EA92F1Q24795473-E1A8EE8D-0A2B-4CB6-B2AB-1137EAC4FE07Q24800452-53387BB1-E308-4BDF-9CBE-EE295939055DQ24802926-1C0586AC-E06D-4C59-969A-3ACCB3D0E18EQ28219351-1EED72C1-9F74-442D-868F-11AC7293022EQ28541226-883F0E8E-9BDD-4D19-A53C-0030B7D36A42Q28570822-C1931822-AC25-47FC-B683-C5E18012E86DQ28943355-CE0D2A4C-8B72-43C0-8499-458618E88538Q30387845-28022A2A-0128-4496-8781-2780CC4343FBQ30494296-F011918E-27DA-498A-929E-0481F07FA1D4Q31016373-65274BAF-EB74-45DF-9D42-E6A4F6FDA93CQ33504435-0779EEF5-6D1A-4EE8-AD59-4CDEE327C609Q33596363-4012CB92-FA85-4115-BB07-6DCBA703C97CQ33609671-38E99994-1F85-4142-BAB2-11C0C244D50CQ33621368-5C9E00D4-F085-4460-8F3E-B6F9838FD325Q33685092-B7F1519E-BBB7-42D5-B312-6BA2DDA67D85Q33716542-DE627C91-9631-4683-8690-BBA3CBA298F8Q33740264-E67D34A7-EAA3-460A-97D2-12F42BBDD266Q33743947-F11C7307-C3F1-419F-B67F-BE2628732141Q33765055-B6DFFD1E-C830-415F-A13E-EE100FDF3D2CQ33891994-9CB67AF1-A4F5-49A6-8825-CDFFBE2BCCA6Q33900376-B4CCCE22-292A-4AB3-B8DD-80988A7EC87FQ33954694-C2AA2700-FABC-4446-91F9-58F7E8F66B90Q33956586-A6917F7F-B674-4CCF-B7AC-9126B71B0236Q34024831-6312D0CA-D284-4EF4-81D9-9073860541F5Q34030074-C40E27B0-8B41-462C-8952-B299BF68BAB8Q34031056-222EA144-C2D3-4AB8-8682-3AE6CA6E1CFAQ34031853-2D5A384A-8D52-422D-B0CF-C0E359EC3494Q34044762-6ED9621A-343D-45EE-8EE5-97B2E603AD17Q34074902-DC4C588D-2DC8-48EB-934B-7D1D46EE92AAQ34158441-F25B29AD-4ABA-4D75-9A5F-87641D20857FQ34180907-5CB012F5-51FD-45D3-93B1-22BA341A6618
P2860
Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Medical expenditures for the t ...... ional Osteoporosis Foundation.
@en
Medical expenditures for the t ...... ional Osteoporosis Foundation.
@nl
type
label
Medical expenditures for the t ...... ional Osteoporosis Foundation.
@en
Medical expenditures for the t ...... ional Osteoporosis Foundation.
@nl
prefLabel
Medical expenditures for the t ...... ional Osteoporosis Foundation.
@en
Medical expenditures for the t ...... ional Osteoporosis Foundation.
@nl
P2093
P2860
P1476
Medical expenditures for the t ...... ional Osteoporosis Foundation.
@en
P2093
P2860
P356
10.1359/JBMR.1997.12.1.24
P577
1997-01-01T00:00:00Z